about
Publishing SNP genotypes of human embryonic stem cell lines: policy statement of the International Stem Cell Forum Ethics Working PartyThe implementation of novel collaborative structures for the identification and resolution of barriers to pluripotent stem cell translation.Advocacy: How to hasten open access.Enabling consistency in pluripotent stem cell-derived products for research and development and clinical applications through material standards.Setting Global Standards for Stem Cell Research and Clinical Translation: TheĀ 2016 ISSCR Guidelines.Direct-to-consumer stem cell marketing and regulatory responsesStem cell stratagems in alternative medicine.Global challenges in stem cell research and the many roads ahead.The unregulated commercialization of stem cell treatments: a global perspective.Global update: Japan.Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations.Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI).Marketing of unproven stem cell-based interventions: A call to action.Industry Responsibilities in Tackling Direct-to-Consumer Marketing of Unproven Stem Cell Treatments.Challenges in the clinical application of induced pluripotent stem cells.SCIENTIFIC COMMUNITY. Confronting stem cell hype.Oversight for clinical uses of autologous adult stem cells: lessons from international regulations.Policy: Global standards for stem-cell research.Global bionetworks and challenges in regulating autologous adult stem cells.Disclosure and management of research findings in stem cell research and banking: policy statement.Show drugs work before selling them.Regulation: Sell help not hope.Global Distribution of Businesses Marketing Stem Cell-Based Interventions.Bioethics in China: No wild east.Identity and ownership issues in the regulation of autologous cells.Cell Churches and Stem Cell Marketing in South Korea and the United States.Regulatory impacts on stem cell research in Japan.Issues in stem cells in Asia and SNAP decisions.Rejuvenating Regenerative Medicine Regulation.Japan Strengthens Regenerative Medicine Oversight.No Vacillation on HPV Vaccination.Undertested and Overpriced: Japan Issues First Conditional Approval of Stem Cell Product.Conditional approval: Japan lowers the bar for regenerative medicine products.Stem cells. U.S. regulation of stem cells as medical products.Ethical and policy issues in the clinical translation of stem cells: report of a focus session at the ISSCR Tenth Annual Meeting.New IJH guidelines highlight greater transparency.2010 International Forum on Stem Cells (November 11-13; Tianjin, China).Gold standards in the diamond age: the commodification of pluripotency.No borders, only frontiers: the Global Stem Cell Research Community and the ISSCR.Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions.
P50
Q28742548-82E0E3B2-7453-4D37-9C4B-EFAF88EB395AQ30424407-2BFC19E5-E517-40F2-92B7-EE5E70CC6167Q30486053-941B5A87-0CA3-47A6-9773-20F9887CE686Q35119693-8A4F5F9B-3C48-4289-B8C2-C61B9E7376DEQ37017086-33864E69-568F-43B1-91EF-2A6346D2E06DQ37124542-6CE990BA-3E8E-48CB-ADD8-7DDD3542EA09Q37859390-F05BFE33-25E9-4B94-A4EC-A946026CB8AFQ37879262-55C32DC0-D962-4749-8790-123EEB1D2D0AQ37941468-01F8CE6F-0240-4F84-A286-9F0F593CE397Q37945697-406D94D9-03AB-4CDE-84BF-18BF462F28CAQ38372717-04A52415-9735-4F3A-B844-67F8CDB9451AQ38910429-03B7BD91-DBDE-42BC-B10E-AFFC1A5105F1Q39416083-CA4A6C14-0438-4C6D-BD05-18D9029A7D01Q39427822-2E18E7F1-C923-49D8-83F6-C29B8D354CA1Q39448496-87DACD2C-22C8-483E-85E4-12E2FA64A12DQ42696355-CFB931EE-7E58-4101-A91E-7BB79B5ADD4DQ43739042-A6AB6AF0-C9A5-419C-B712-26CEE2A58498Q45886082-C4594608-39B8-4A98-841D-16BCE01DE220Q45939139-3618659A-993D-4C2D-878D-92C1B2805DD2Q46015256-56D6DC88-87EA-4CF6-B337-A0578BFFC424Q47571152-D2F351F6-9559-46E0-B435-B254BCB99093Q47593397-1022A85F-E565-4063-A498-80A60B75CADEQ47610375-7851A720-1E68-40FB-A960-AA340FE5F6E6Q47716825-DCEA6C04-A33A-4912-BEF4-E7EF01D77741Q47852426-550A6D46-8C62-41F5-80EF-3097832587A8Q48225466-A0DBC836-7428-4BAE-AB5A-B69440EEB0DEQ48819349-C52D0215-7F83-4194-AAFC-4C25B2E9FEE7Q49933532-82BA1CF3-866D-4077-9FC5-D23E5472A43AQ50103315-45C0693D-7AAC-4763-8115-A86416BC872BQ50209903-003931F1-C87D-44E2-97A0-0A3F00A64E07Q50420156-DD4A9E1E-CA98-4541-8F4C-2C1020D014E2Q50522119-F1C5BBF8-4893-416D-B9C8-ADD3BC75BB53Q50593192-E6105C9D-F628-49E7-991B-DF56D63D754FQ50771347-F64BB09D-FA82-4A7B-BD98-5D6B8C0A01E5Q51200315-FA5BF574-8079-47F5-8D82-E1A6F89B0266Q51873968-DD408D0E-9F1B-4219-8457-133897AC11F3Q51887529-AEFE3423-C6AA-4B99-89EF-9BA859B78E37Q51925336-ABFD7775-9A68-49A4-A7DE-447C2A7A439AQ51960993-BB8D57A5-B48E-407B-B2CF-4BFBC518D851Q52686004-ECE09B8A-6E6A-44E1-9606-FDA2023318AE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
Õ°Õ„ÕæÕ”Õ¦ÕøÕæÕøÕ²
@hy
name
Douglas Sipp
@ast
Douglas Sipp
@en
Douglas Sipp
@es
Douglas Sipp
@nl
Douglas Sipp
@sl
type
label
Douglas Sipp
@ast
Douglas Sipp
@en
Douglas Sipp
@es
Douglas Sipp
@nl
Douglas Sipp
@sl
prefLabel
Douglas Sipp
@ast
Douglas Sipp
@en
Douglas Sipp
@es
Douglas Sipp
@nl
Douglas Sipp
@sl
P106
P21
P31
P496
0000-0002-5979-0938